About Ictero Medical
Ictero Medical, Inc. develops a minimally invasive treatment for gallstone disease. Its cryoablation system is built to treat the disease without removing the gallbladder. The company aims it at high-risk patients with gallstone disease. It uses existing interventional techniques to deliver the cryoablation therapy.
Ictero is based in Houston, Texas, and came out of the Texas Medical Center Biodesign fellowship. Matthew Nojoomi and David Waters are co-founders, and Raymond Kirk is CMO. Manish Ahuja is the company's CEO. In April 2022 Ictero raised a $6 million Series A round led by MedTex Ventures and S3 Ventures.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | Nov 5, 2026 | $344,404of $695K target | 9 | $38,267 | EquityRule 506(b) | Form D ↗ |
| Dec 31, 2021 | Feb 1, 2022amended Apr 28, 2022 | $7,148,111fully sold | 22 | $324K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Total, two offerings | $7,492,515 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Rounds announced by Ictero Medical
What the company said publicly about its funding. Announced amounts can differ from Form D figures: an announcement can combine several closings, and some money is raised without a Form D.
| Announced | Round | Amount | Investors | Source |
|---|---|---|---|---|
| Apr 29, 2022 | Series A | $6 million | MedTex Ventures, S3 Ventures (lead), An undisclosed strategic investor | Ictero Medical Closes $6M Series A Financing (Business Wire) ↗ Ictero Medical Closes $6M Series A Financing (copy on MedTech Innovator) ↗ |
Why Investors Backed Ictero Medical
Ictero Medical is a Houston medical device company developing a gallstone treatment that leaves the gallbladder in place. It raised a $6 million Series A round in April 2022, led by MedTex Ventures and S3 Ventures. The company grew out of the Texas Medical Center Biodesign fellowship. Its focus is high-risk patients, whom the company calls underserved.
The problem it targets
In Ictero's account, more than 1 million U.S. patients a year have their gallbladders removed to treat symptomatic gallstones. It sees a large, underserved group of high-risk patients who would benefit from an alternative to surgery. Co-founder Matthew Nojoomi said in 2022 that the technology gives critically ill patients an immediate option, since they have no good treatment today. He added that it could also help healthier patients who want to avoid surgery.
What the product does
The system uses existing interventional techniques to deliver cryoablation therapy. The therapy is meant to put the gallbladder out of action without taking it out. S3 Ventures describes the system as minimally invasive. The company's site names its gallstone treatment the CholeSafe System.
Progress so far
The Series A money is meant to fund more product development and finish initial clinical testing. The stated aim is regulatory clearance. Ictero also partnered with Biotex, a Houston medical device development firm. The partnership gives Ictero engineering resources and in-house manufacturing capabilities.
Who backs it
MedTex Ventures and S3 Ventures led the round, together with an undisclosed strategic investor. MedTex also backs Ictero through its Biotex Medical Device Fund, as part of the Biotex partnership. S3 Ventures lists Texas HALO Fund, TMC Venture Fund and the Texas Medical Center as co-investors in Ictero.
We wrote this summary from public statements by Ictero Medical and its investors. It is not investment advice.
Ictero Medical in the News
Leadership Team
Executive officers and directors listed on Ictero Medical's Form D filed Nov 5, 2026.
Earlier filings also listed Matthew Nojoomi (ceo and director, last listed Apr 2022) and David Waters (executive officer, last listed Apr 2022).